Evidence map›Paper›PMID 30524382›Full record

ArticleFrontiers in microbiology2018

A Population-Based Descriptive Atlas of Invasive Pneumococcal Strains Recovered Within the U.S. During 2015-2016.

Bernard Beall, Sopio Chochua, Robert E Gertz, Yuan Li, Zhongya Li, Lesley McGee, Benjamin J Metcalf, Jessica Ricaldi, Theresa Tran, Hollis Walker and 1 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. AMicrobial genomics · 2022
    Article
  17. Population structure of ocularMicrobial genomics · 2022
    Article
  18. Article
  19. Article
  20. Microbial genomics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bernard BeallRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Sopio ChochuaRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Robert E GertzRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Yuan LiRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Zhongya LiRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Lesley McGeeRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Benjamin J MetcalfRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Jessica RicaldiRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Theresa TranRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Hollis WalkerRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Tamara PilishviliRespiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive pneumococcal disease (IPD) has greatly decreased since implementation in the U.S. of the 7 valent conjugate vaccine (PCV7) in 2000 and 13 valent conjugate vaccine (PCV13) in 2010. We used whole genome sequencing (WGS) to predict phenotypic traits (serotypes, antimicrobial phenotypes, and pilus determinants) and determine multilocus genotypes from 5334 isolates (~90% of cases) recovered during 2015-2016 through Active Bacterial Core surveillance. We identified 44 serotypes; 26 accounted for 98% of the isolates. PCV13 serotypes (inclusive of serotype 6C) accounted for 1503 (28.2%) isolates, with serotype 3 most common (657/5334, 12.3%), while serotypes 1 and 5 were undetected. Of 305 isolates from children <5 yrs, 60 (19.7%) were of PCV13 serotypes 19A, 19F, 3, 6B, and 23F (58/60 were 19A, 19F, or 3). We quantitated MLST-based lineages first detected during the post-PCV era (since 2002) that potentially arose through serotype-switching. The 7 predominant emergent post-PCV strain complexes included 23B/CC338, 15BC/CC3280, 19A/CC244, 4/CC439, 15A/CC156, 35B/CC156, and 15BC/CC156. These strains accounted for 332 isolates (6.2% of total) and were more frequently observed in children <5 yrs (17.7%; 54/305). Fifty-seven categories of recently emerged (in the post PCV7 period) putative serotype-switch variants were identified, accounting for 402 isolates. Many of these putative switch variants represented newly emerged resistant strains. Penicillin-nonsusceptibility (MICs > 0.12 μg/ml) was found among 22.4% (1193/5334) isolates, with higher penicillin MICs (2-8 μg/ml) found in 8.0% (425/5334) of isolates that were primarily (372/425, 87.5%) serotypes 35B and 19A. Most (792/1193, 66.4%) penicillin-nonsusceptible isolates were macrolide-resistant, 410 (34.4%) of which were

Indexed as

antibiotic resistanceclonal complex (CC)conjugate vaccinepneumococcalserotype distributionsserotype diversity

Identifiers

PMID30524382
PMCPMC6262371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.